Search

Your search keyword '"Vucinic, Vladan"' showing total 736 results

Search Constraints

Start Over You searched for: Author "Vucinic, Vladan" Remove constraint Author: "Vucinic, Vladan"
736 results on '"Vucinic, Vladan"'

Search Results

2. Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma

3. Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT

4. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

5. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

6. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

9. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma

10. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

11. Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

12. Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study

13. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis

14. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

15. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

17. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

20. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

21. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients

23. A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

24. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

25. ATMP: der Weg in die Klinik

26. Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15

27. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin

28. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

30. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

31. Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

33. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

36. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

37. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

38. Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients

39. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (Car) T Cell Treatment for Relapsed/Refractory Multiple Myeloma

40. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

41. Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment.

42. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

43. Bendamustine, prednisone and bortezomib (BPV) induction therapy prior autologous stem cell transplantation (ASCT) in 135 newly diagnosed multiple myeloma patients: comparison between patients with normal and impaired renal function

46. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

47. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation

48. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

49. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

50. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients

Catalog

Books, media, physical & digital resources